RE: More Reasons to be Cheerful15 May 2023 17:05
Yes and don't forget that GDR has recently guided the market on revenue numbers moving forwards. In summary this includes in the short term 6-8 UK Hospitals being either "fully operational" or in "approved and beginning implementation" mode with the GDR MT-RNR1 ID Kit.
It's also worth pointing out that that the roll out of GDR's MT-RNR1 ID Kit across the UK is worth up to £8.5 million (EACH YEAR), based on approximately 100,000 NICU admissions with an approx customer price per test of £80+.
We also know that the EU market is up to £46.8 million (each and every year), that the U.S. market is worth approx £34 million each year and the rest of the world market equates to £13.8 million every year.
Whilst GDR MT-RNR1 ID Kit is a big revenue winner for GDR it is infact our CYP2C19 ID Stroke Kit, which is targeting the most common type of stroke, which will provide even bigger UK revenuesfor GDR. i.e. £8.5 million to GDR each year (based on approximately 85,000 strokes pa), with EU revenue each year up to £93.5 million (based on 800,000 strokes per year) and even bigger is the U.S. market which is worth up to £67.6 million to GDR every year (based on 700,000 strokes each year). Plus, the rest of the world market is worth £51.0 million EVERY YEAR to GDR.
As I and many others on here have pointed out before these numbers are impressive and will easily eventually support a share price in the hundreds of pence and a market cap to match.
Good luck, Brighty
Sign In
Follow the stocks
